Journal of Crohn's & colitis最新文献

{"title":"Results of the 9th Scientific Workshop of the European Crohn's and Colitis Organisation (ECCO): Artificial Intelligence in IBD: Regulatory and Methodological Considerations.","authors":"Nurulamin M Noor, Marco Daperno, Jan de Laffolie, Aart Mookhoek, Pieter Sinonquel, Uri Kopylov, Bram Verstockt, Alaa El-Hussuna, Kapil Sahnan, Mariangela Allocca, Peter Bossuyt, Dan Carter, Arzu Ensari, Marietta Iacucci, Urko M Marigorta, Daniele Noviello, Gianluca Pellino, Alessandra Soriano, Isabelle Cleynen, Tim Raine, Shaji Sebastian, Daniel C Baumgart","doi":"10.1093/ecco-jcc/jjaf136","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf136","url":null,"abstract":"<p><p>With the rapid growth of artificial intelligence (AI) applications in the field of inflammatory bowel disease (IBD), an increasing number of regulatory and methodological considerations have become apparent. Currently, there remains much uncertainty and limited experience in the field of IBD regarding some of the regulatory and methodological pitfalls to be considered when developing and deploying AI applications for positive clinical and health system impact. Accordingly, an expert panel was convened by the European Crohn's and Colitis Organisation (ECCO) to review the published literature and provide an overview of key regulatory aspects for the application of AI in IBD. This article discusses and, where possible, provides guidance on key methodological and regulatory considerations for AI in IBD. Topics covered include: potential clinical application-focused algorithm design; ethical, moral and legal considerations; regulatory agency perspectives; an overview of regulatory submission and consideration of reimbursement. By providing clinicians with a primer to key regulatory and methodological considerations, we hope to accelerate knowledge translation and implementation of AI-enabled digital health innovations in clinical practice and ultimately improve outcomes for people living with and caring for those living with IBD.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of the Ninth Scientific Workshop of the European Crohn's and Colitis Organisation (ECCO): Artificial intelligence in IBD surgery: opportunities and limitations.","authors":"Alaa El-Hussuna, Gianluca Pellino, Alessandra Soriano, Kapil Sahnan, Aart Mookhoek, Pieter Sinonque, Mariangela Allocca, Dan Carter, Arzu Ensari, Marietta Iacucci, Uri Kopylov, Bram Verstockt, Daniel C Baumgart, Nurulamin M Noor, Urko M Marigorta, Daniele Noviello, Peter Bossuyt, Jan de Laffolie, Marco Daperno, Tim Raine, Isabelle Cleynen, Shaji Sebastian","doi":"10.1093/ecco-jcc/jjaf135","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf135","url":null,"abstract":"<p><p>In this narrative review we present the current status of developments in artificial intelligence in the filed of IBD surgery. We lay down the foundations for how IBD surgery may utilise the potential opportunities in utilizing the rapid advances in AI technology as it used in other surgical disciplines. The main areas of potential utility are in the areas of surgical training, risk prediction in the pre, intra and post operative period in IBD patients undergoing surgery and in IBD surgical research. We need to be mindful of the potential challenges in implementation and acceptability of these technological advances and put in mitigating measures to ensure transparency and equitable access. Global collaboration will be the cornerstone for such ventures.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcome Measures Poorly Correlate with Objective Inflammatory Bowel Disease Activity Measures: A Systematic Review.","authors":"Xavier Calvet, Maria Giovanna Ferrario, Vanessa Marfil, Santos Armenteros, Manuel Barreiro-de Acosta","doi":"10.1093/ecco-jcc/jjaf132","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf132","url":null,"abstract":"<p><strong>Background and aims: </strong>We investigated the correlations between patient-reported outcome measures (PROMs) and other measures of inflammatory bowel disease (IBD) activity.</p><p><strong>Methods: </strong>A systematic literature review was performed up to June 2022. Searches were conducted in PubMed, Scopus and Web of Science. A descriptive analysis was performed. The search protocol was registered in PROSPERO (CRD42022383899).</p><p><strong>Results: </strong>Nineteen studies assessed correlations between PROMs and clinical, endoscopic, and laboratory measures of disease activity in IBD. In Crohn's disease (CD), weak positive correlations were reported for PROMs (e.g. the two-item patient reported outcome [PRO-2], mobile Health Index [mHI] for CD) and endoscopic scores, more often the Simple Endoscopic Score for CD (SES-CD). In ulcerative colitis (UC), PROMs like PRO-2, the Monitor IBD at Home rectal bleeding item and the mHI, showed weak-to-moderate correlations with the Mayo endoscopic subscore (MES). PROMs also demonstrated limited concordance with laboratory measures such as faecal calprotectin (FCP) and C-reactive protein (CRP) in both CD and UC. The substantial heterogeneity in study designs precluded a structured analysis.</p><p><strong>Conclusions: </strong>Although current PROMs offer valuable complementary insights into IBD control from the patient's perspective, they cannot replace objective measures of IBD activity. Future research should focus on refining PROMs and generating composite indices to improve their accuracy and usefulness.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Network Meta-analysis of Capsule Endoscopy Versus Imaging Modalities for Diagnosing Small Bowel Crohn's Disease.","authors":"Shahryar Khan, Dushyant Singh Dahiya, Ahmed Khan Jadoon, Danish Ali Khan, Mashal Alam Khan, Falak Hamo, Hameed Ullah, Hareesha Rishab Bharadway, Yousaf Zafar, Sanket Basida, Shadi Hamdeh","doi":"10.1093/ecco-jcc/jjaf127","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf127","url":null,"abstract":"<p><strong>Introduction: </strong>Clinicians have several imaging options to evaluate suspected or confirmed small bowel Crohn's disease (SB-CD), including computed tomography enterography (CTE), magnetic resonance enterography (MRE), intestinal ultrasound (IUS), and video capsule endoscopy (VCE).</p><p><strong>Methods: </strong>Direct head-to-head comparative analysis and network meta-analysis were conducted on all available modalities using a random effects model. Furthermore, each modality was ranked using the surface under the cumulative ranking curve approach (P-score).</p><p><strong>Results: </strong>The present review included 29 studies with a total population of 2,609 individuals. The pooled sensitivity, specificity and diagnostic accuracy for the detection of SB-CD were 89.6%, 86.2% and 71.5% for VCE; 82%, 71.6% and 67.9% for MRE; 79.6%, 82.7% and 52.3% for CTE; and 89.3%, 72% and 71% for IUS, respectively. The network meta-analysis found that VCE exhibited superior diagnostic accuracy compared to CTE and MRE, while demonstrating comparable performance between VCE and IUS, as well as among MRE, CTE, and IUS. Further, the ranking analysis positioned VCE (P-score 0.97) as the most effective diagnostic modality for SB-CD, followed by IUS, MRE, and CTE. Subgroup analysis showed that VCE had significantly better diagnostic accuracy than the other modalities for detecting proximal SB-CD. Regarding adverse events, VCE was associated with capsule retention in 3.3% of the cases in these studies.</p><p><strong>Conclusions: </strong>VCE exhibited superior diagnostic performance for detecting established proximal SB-CD compared to other imaging modalities. Clinicians should weigh the benefits and risks, and incorporate other modalities, such as MRE and IUS to optimize diagnosis and management.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ECCO Consensus on Dietary Management of Inflammatory Bowel Disease.","authors":"Vaios Svolos, Hannah Gordon, Miranda C E Lomer, Marina Aloi, Aaron Bancil, Alice S Day, Andrew S Day, Jessica A Fitzpatrick, Konstantinos Gerasimidis, Konstantinos Gkikas, Lihi Godny, Charlotte R H Hedin, Konstantinos Katsanos, Neeraj Narula, Richard K Russell, Chen Sarbagili-Shabat, Jonathan P Segal, Rotem Sigall-Boneh, Harry Sokol, Catherine L Wall, Kevin Whelan, Eytan Wine, Henit Yanai, Richard Hansen, Emma P Halmos","doi":"10.1093/ecco-jcc/jjaf122","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf122","url":null,"abstract":"","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ECCO consensus on management of Inflammatory Bowel Disease in low-and middle-income countries.","authors":"Alaa El-Hussuna, Almuthe Christina Hauer, Tarkan Karakan, Valerie Pittet, Henit Yanai, Jalpa Devi, Jesus K Yamamoto-Furusho, Ali Reza Sima, Hailemichael Desalegn, Mutaz Idrees Sultan, Vishal Sharma, Hany Shehab, Lamya Mrabti, Natalia Queiroz, Anuraag Jena, Andy Darma, Karin Davidson, Nicolas Avellaneda, Muhammed Elhadi, April Roslani, Dakshitha Wickramasinghe, Carlo Angelo Cajucom, Shaji Sebastian","doi":"10.1093/ecco-jcc/jjaf125","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf125","url":null,"abstract":"<p><strong>Background: </strong>The incidence and prevalence of inflammatory bowel disease [IBD] have increased significantly in low- and middle-income countries [LMICs] in recent decades. Managing IBD in these settings presents substantial challenges. This consensus aims to describe the epidemiology of IBD in LMICs and to highlight the key challenges in its diagnosis and treatment.</p><p><strong>Method: </strong>The consensus-defining strategy followed the previous European Crohn's and Colitis Organisation [ECCO] consensus guidelines [available at www.ecco-ibd.eu]. The authors reviewed the available evidence and formulated statements accordingly. Provisional ECCO statements and supporting text were drafted based on a comprehensive literature review and further refined through two voting rounds, which included external reviewers and national representatives from ECCO's 36 member countries. The final ECCO statements, representing a consensus of at least 80% agreement among participants, were approved during an online meeting. Consensus statements should be interpreted in context with their accompanying commentary rather than in isolation and should not be used solely to guide patient management. The supporting text was finalized under the guidance of each working group leader [VP, HY, TK, AH] and subsequently integrated by the consensus leader [AE].</p><p><strong>Results: </strong>Data on IBD epidemiology in LMICs remain limited. Public and healthcare professional awareness and timely access to early diagnostic modalities, advanced medical and surgical therapies, and specialist multidisciplinary care are key gaps in IBD care in LMICs. The complexity and chronic nature of IBD, along with the necessity for a multidisciplinary approach, pose significant challenges to adopting a holistic management strategy in LMICs.</p><p><strong>Conclusion: </strong>There is a critical need for further studies to assess the specific needs of LMICs. Such research will help guide resource allocation and improve IBD management in these settings.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint.","authors":"Jean-Frederic Colombel, Jianmin Wu, Taku Kobayashi, Baojin Zhu, Jerome Paulissen, Agni Dhanabal, Vipul Jairath, Corey Siegel, Britta Siegmund, Isabel Redondo, Richard Moses, Fernando Magro","doi":"10.1093/ecco-jcc/jjaf124","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf124","url":null,"abstract":"<p><strong>Background and aims: </strong>Concurrent achievement of symptomatic, endoscopic, and histologic remission, known as disease clearance, has been proposed as a treatment target in ulcerative colitis. Mirikizumab, an anti-interleukin-23 p19 antibody, has demonstrated long-term efficacy and safety, as reported in the LUCENT Phase 3 trials (NCT03518086, NCT03524092, and NCT03519945). The current analysis evaluates the impact of mirikizumab on disease clearance and the association with other clinical and patient-reported outcomes (PROs).</p><p><strong>Methods: </strong>LUCENT methods have previously been reported. The proportion of patients achieving disease clearance was determined through week (W)104. Association analyses were assessed between disease clearance and PROs (IBDQ, SF-36, WPAI:UC, PGRS, and PGRC), and early disease clearance and subsequent clinical outcomes (clinical, corticosteroid-free, endoscopic, histological, histologic-endoscopic, bowel urgency, stool frequency, and rectal bleeding).</p><p><strong>Results: </strong>The proportions of patients achieving disease clearance with mirikizumab at W12, W52, and W104 were 16.0%, 36.4%, and 51.3%, respectively. Mirikizumab-treated patients with disease clearance showed greater PRO improvements through W52 than those without. Early clearance at W12 was associated with significantly better clinical outcomes at later time points, except for bowel urgency remission at W52. This trend was repeated for clinical outcomes at W104 in patients who achieved disease clearance at W52.</p><p><strong>Conclusions: </strong>Mirikizumab consistently demonstrated disease clearance across induction, maintenance, and long-term studies. The attainment of disease clearance was associated with greater improvement in PROs, and early achievement of disease clearance was associated with better long-term outcomes, including clinical remission, corticosteroid-free remission, endoscopic and histological outcomes, reduced stool frequency, and rectal bleeding.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal hematopoiesis of indeterminate potential and risk of incident Crohn's disease-a prospective cohort study.","authors":"Yuqing Wang, Huiwen Xue, Ola Olén, Åsa H Everhov, Hui Wei, Qifa Liu, Qianwei Liu","doi":"10.1093/ecco-jcc/jjaf118","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf118","url":null,"abstract":"<p><strong>Background and aims: </strong>Crohn's disease (CD) is a chronic immune-mediated inflammatory disorder. Its pathophysiology involves dysregulation of both innate and adaptive immune responses, which can occur in clonal hematopoiesis of indeterminate potential (CHIP) individuals. Therefore, we hypothesize that CHIP may influence CD incidence. However, no study has explored the association between CHIP and incident CD. We analyzed UK Biobank data to investigate the association between CHIP and incident CD.</p><p><strong>Methods: </strong>CHIP was defined based on the whole-exome sequencing data. The outcome was incident CD. Cox regression models were used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for CD in relation to CHIP.</p><p><strong>Results: </strong>This study included 461,913 participants, of whom 14,339 (3.1%) had CHIP. The incidence rate of CD was 21.6 and 37.7 per 100,000 person-years for individuals without and with CHIP, respectively. We found a statistically significant increased risk of CD among individuals with CHIP (HR: 1.68; 95% CI: 1.30-2.16), compared with the reference group. This association was particularly stronger in individuals with JAK2-mutant CHIP (HR: 7.28; 95% CI: 1.82-29.13), ASXL1-mutant CHIP (HR: 3.07; 95% CI: 1.74-5.44) and DNMT3A-mutant CHIP (HR: 1.73; 95% CI: 1.24-2.42). Additionally, the association did not vary greatly by demographic, socioeconomic, lifestyle factors, CHIP clone size, or cancer comorbidity.</p><p><strong>Conclusions: </strong>CHIP was associated with a markedly increased risk of subsequent CD. The association was particularly stronger in JAK2-mutant CHIP, ASXL1-mutant CHIP, and DNMT3A-mutant CHIP. The findings of this study may offer potential insights for future investigations into the mechanistic underpinnings of CD.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scoring indices for assessing endoscopic disease activity in acute severe ulcerative colitis: A systematic review.","authors":"Hadar Meringer, Maia Kayal, Vipul Jairath, Anila Qasim, John K MacDonald, Yuhong Yuan, Christopher Ma, Jean-Frederic Colombel","doi":"10.1093/ecco-jcc/jjaf126","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf126","url":null,"abstract":"<p><strong>Background and aims: </strong>Endoscopy is important for assessing disease severity and potentially predicting treatment response in acute severe ulcerative colitis (ASUC). We aimed to identify and determine the operating properties of existing endoscopic indices/items used to assess disease activity in ASUC.</p><p><strong>Methods: </strong>MEDLINE, Embase, and Cochrane CENTRAL were searched from database inception to 17 April 2024 to identify individual items and scoring indices used to evaluate endoscopic disease activity in patients with ASUC. Subsequently, we performed another comprehensive search from database inception to 29 July 2024 to identify studies that assessed the validity, reliability, feasibility and responsiveness of the identified items and scoring indices.</p><p><strong>Results: </strong>We identified 18 studies that reported endoscopic measures in patients with ASUC, including Endoscopic Activity Index, Mayo endoscopic subscore (MES), Severe Endoscopic Lesions, Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score or sub-components of these indices. A total of 33 studies evaluated the operating properties of the MES, UCEIS, and DUBLIN score in ASUC. The MES and the UCEIS demonstrated adequate discriminant construct validity, convergent construct validity, and responsiveness. Feasibility or reliability were not assessed for these scores. The DUBLIN score demonstrated indeterminate discriminant construct validity and convergent construct validity with limited data. Responsiveness, feasibility, and reliability were not assessed for this score.</p><p><strong>Conclusions: </strong>These results highlight the need for a validated endoscopic score that can accurately describe and quantify the severity of endoscopic lesions and potentially predict outcomes in ASUC patients.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Risk of Mild, Moderate, and Severe Infections in IBD patients - A prospective, multicentre observational cohort study (PRIQ).","authors":"Ashkan Rezazadeh Ardabili, Dirk Van Esser, Dion Wintjens, Mia Cilissen, Debbie Deben, Zlatan Mujagic, Fritzi Russ, Laurents Stassen, Adriaan Van Bodegraven, Dennis Wong, Bjorn Winkens, Daisy Jonkers, Mariëlle Romberg-Camps, Marieke Pierik","doi":"10.1093/ecco-jcc/jjaf112","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf112","url":null,"abstract":"<p><strong>Background: </strong>In light of the growing number of treatment options, the benefit-risk balance of IBD drugs is increasingly important in clinical decision-making. Post-marketing surveillance studies are pivotal to assess infection risk, yet mainly focus on severe infections. This study aimed to assess the incidence and risk factors associated with mild, moderate, and severe infections in IBD patients.</p><p><strong>Methods: </strong>We previously developed and validated a Patient-Reported Infections Questionnaire (PRIQ) which accurately assesses 15 infection categories with a 3-month recall period. The current prospective, multicentre, observational cohort study was performed between June 1, 2020 and July 1, 2021, enrolling consecutive IBD patients using myIBDcoach. Incidence rates (IR) were calculated for all infections and negative binomial regression was utilized to identify risk factors for infections over time.</p><p><strong>Results: </strong>In total, 629 IBD patients (n=346 CD, n=283 UC, 58.3% female) were included, completing 2397 PRIQs during 573.8 person-years (PY) of follow-up. This resulted in 991 reported infections and an overall IR of 172.7 per 100PY, predominantly characterized by mild (IR 117.5 per 100PY) and moderate (IR 50.9 per 100PY) infections. Risk factors significantly associated with increased overall infection rates included female sex, higher comorbidity burden, smoking, and specific treatments, such as steroids, immunomodulators, anti-TNF agents, and JAK-inhibitors, with steroids doubling infection risk (IRR 2.02).</p><p><strong>Conclusion: </strong>Mild and moderate infections are common among IBD patients and are particularly associated with both patient characteristics and specific immunosuppressive treatments. These findings emphasize the need for vigilant monitoring, especially for patients at higher infection risk, and allow for more personalized advice on benefit-risk of IBD treatments.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}